---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084086"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2026-07-16T11:53:02+00:00"
generated_at: "2026-07-16T11:55:04.442419+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Gain Therapeutics updates cash runway; expects funding into Q2 2027

## Summary
- Cash and equivalents expected to fund operations into Q2 2027 based on current plans.
- Phase 1b open-label extension completion expected in October 2026.
- Phase 2 clinical study initiation planned for Q3 2026.

## SEC filing metadata
- accession: 0001104659-26-084086
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2026-07-16T11:53:02+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465926084086/0001104659-26-084086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465926084086/tm2620618d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084086
- JSON: https://secwatch.observer/filing/0001104659-26-084086.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.